Minimum Five-Year Outcomes of Hip Resurfacing: Propensity-Score Matched Against Total Hip Arthroplasty Control Groups

J Arthroplasty. 2021 Jun;36(6):2012-2015. doi: 10.1016/j.arth.2021.01.042. Epub 2021 Jan 21.

Abstract

Background: The aim of this study is to evaluate clinical outcomes of patients undergoing Birmingham hip resurfacing (BHR) with a minimum 5-year follow-up and compare these outcomes to 2 matched control groups of patients undergoing either direct anterior approach (DAA) or posterior approach (PA) total hip arthroplasty (THA).

Methods: Data between September 2008 and April 2015 were retrospectively reviewed. Male patients were included if they underwent a THA or BHR with minimum 5-year patient-reported outcomes. BHR patients were propensity-score matched in a 1:1 ratio to 2 control groups of patients: one group who underwent DAA THA and one group who underwent PA THA.

Results: Fifty BHR patients were propensity-score matched to 2 control groups: 50 cases of PA THA and 50 cases of DAA THA. Both control groups were well matched with respect to demographics. The BHR 5-year patient-reported outcomes were comparable to both control groups. The BHR cohort compared favorably to the PA THA group with no significant differences in their average Forgotten Joint Score (77.9, 79.4, P = .84 respectively) and the number of patients reporting a score greater than or equal to 50 were also comparable, 41 (82%), 42 (84%), P = .79 respectively.

Conclusion: BHR yielded good functional status and outcomes, which compared favorably with control groups of DAA THA and PA THA. Decision-making should be based upon other factors such as potential risk factors, the surgeon's and patient's preferences, and the patient's physical demand.

Keywords: 5-year outcomes; Birmingham hip resurfacing; clinical outcomes; forgotten joint score; total hip arthroplasty.

MeSH terms

  • Antiviral Agents
  • Arthroplasty, Replacement, Hip*
  • Control Groups
  • Humans
  • Male
  • Propensity Score
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Antiviral Agents